非缺血性扩张型心肌病基因变异与结局的关联研究
该多中心回顾性研究纳入1005例基因分型的非缺血性扩张型心肌病先证者,其中372例(37%)携带致病或可能致病变异。中位随访4.04年,基因阳性组主要不良心血管事件、终末期心衰及恶性室性心律失常风险均显著高于基因阴性组,且左室逆重构率更低。不同受累基因的临床结局存在差异。
要点
- 基因阳性DCM患者主要不良心血管事件风险较基因阴性者增加51%。
- 基因阳性与终末期心衰及恶性室性心律失常风险升高相关。
- 不同致病基因对应的左室逆重构和临床结局存在差异。
核心结论
- 携带致病或可能致病变异的DCM患者预后较基因阴性者更差。
- 临床病程因受累基因不同而异。
研究设计与样本
- 多中心回顾性队列研究,纳入1005例基因分型的非缺血性DCM先证者,来自20个中心。
- 372例(37%)为基因阳性(致病或可能致病变异),633例(63%)为基因阴性。
主要发现
- 中位随访4.04年(IQR 1.70-7.50年),主要终点在基因阳性组发生118例(31.7%),基因阴性组125例(19.8%)(HR 1.51,95%CI 1.17-1.94,P=0.001)。
- 终末期心衰在基因阳性组发生60例(16.1%),基因阴性组55例(8.7%)(HR 1.67,95%CI 1.16-2.41,P=0.006)。
- 恶性室性心律失常在基因阳性组发生73例(19.6%),基因阴性组77例(12.2%)(HR 1.50,95%CI 1.09-2.07,P=0.013)。
- 左室逆重构在基因阳性组发生率为39.6%,基因阴性组为46.2%(P=0.047)。
- 基线左室射血分数≤35%者中,基因阳性患者的主要不良心血管事件、终末期心衰及恶性室性心律失常均多于基因阴性者(所有P<0.02)。
临床怎么用
- 对DCM患者进行基因检测有助于识别预后更差的高危亚组。
- 基因阳性尤其合并左室射血分数≤35%者需更密切监测心衰和心律失常事件。
局限性
- 回顾性研究设计可能引入偏倚。
- 随访时间中位4.04年,长期结局未明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The clinical relevance of genetic variants in nonischemic dilated cardiomyopathy (DCM) is unsettled. OBJECTIVES: The study sought to assess the prognostic impact of disease-causing genetic variants in DCM. METHODS: Baseline and longitudinal clinical data from 1,005 genotyped DCM probands were retrospectively collected at 20 centers. A total of 372 (37%) patients had pathogenic or likely pathogenic variants (genotype positive) and 633 (63%) were genotype negative. The primary endpoint was a composite of major adverse cardiovascular events. Secondary endpoints were end-stage heart failure (ESHF), malignant ventricular arrhythmia (MVA), and left ventricular reverse remodeling (LVRR). RESULTS: After a median follow-up of 4.04 years (interquartile range: 1.70-7.50 years), the primary endpoint had occurred in 118 (31.7%) patients in the genotype-positive group and in 125 (19.8%) patients in the genotype-negative group (hazard ratio [HR]: 1.51; 95% confidence interval [CI]: 1.17-1.94; P = 0.001). ESHF occurred in 60 (16.1%) genotype-positive patients and in 55 (8.7%) genotype-negative patients (HR: 1.67; 95% CI: 1.16-2.41; P = 0.006). MVA occurred in 73 (19.6%) genotype-positive patients and in 77 (12.2%) genotype-negative patients (HR: 1.50; 95% CI: 1.09-2.07; P = 0.013). LVRR occurred in 39.6% in the genotype-positive group and in 46.2% in the genotype-negative group (P = 0.047). Among individuals with baseline left ventricular ejection fraction ≤35%, genotype-positive patients exhibited more major adverse cardiovascular events, ESHF, and MVA than their genotype-negative peers (all P < 0.02). LVRR and clinical outcomes varied depending on the underlying affected gene. CONCLUSIONS: In this study, DCM patients with pathogenic or likely pathogenic variants had worse prognosis than genotype-negative individuals. Clinical course differed depending on the underlying affected gene.
引用
- Escobar-Lopez L, Ochoa JP, Mirelis JG, et al. Association of Genetic Variants With Outcomes in Patients With Nonischemic Dilated Cardiomyopathy. J Am Coll Cardiol. 2021. PMID: 34674813. doi:10.1016/j.jacc.2021.08.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。